Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
ISP
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc….
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of…
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of…
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a…
Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) — EPIC BIO, a biotechnology company…
Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) — EPIC BIO, a biotechnology company…
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023
LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen”), an online global…
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023
LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen”), an online global…
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for…
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
– Oral presentation highlights EPI-321 effects on multiple clinically relevant markers – – IND application…
Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
– Company’s metagenomics-derived gene editing toolbox shows activity, specificity, and translatability for broad use in…
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…
Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate Update
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES….
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Erick Lucera Editas Medicine today…
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Erick Lucera Editas Medicine today…